TY - JOUR
T1 - Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4 + T cell activation.
AU - Carrión, Flavio
AU - Nova, Estefania
AU - Luz, Patricia
AU - Apablaza, Felipe
AU - Figueroa, Fernando
N1 - Funding Information:
This work was supported by grant MED-004-7 from Universidad de los Andes and grant Innova Chile Corfo 205-4350. The authors thanks A.M. Avalos, C. Irrarazabal for critical review of the manuscrip and C. Campos for help with MSCs cultures.
PY - 2011/3/30
Y1 - 2011/3/30
N2 - Mesenchymal stem cells (MSCs) are multipotent progenitors with broad immunosuppressive properties. However, their therapeutic use in autoimmune disease models has shown dissimilar effects when applied at different stages of disease. We therefore investigated the effect of the addition of MSCs on the differentiation of Th1, Treg and Th17 cells in vitro, at different states of CD4 + T cell activation. CD4 + T lymphocytes purified by negative selection from mouse C57BL/6 splenocytes were cultured under Th1, Th17 and Treg inducing conditions with IL-12, TGF-β+IL-6 or TGF-β, respectively. C57BL/6 bone marrow derived MSCs were added to CD4 + T cell cultures at day 0 or after 3 days of T cell polarizing activation. Intracellular cytokines for Th1, Th17 and Treg cells were quantitated at day 6 by flow cytometry. While early addition (day 0) of MSCs suppressed all CD4 + T cell lineages, addition at day 3 only decreased IFN-γ production by Th1 polarized cells by 64% (p<0.05) while markedly increased IL-17 production by Th17 polarized cells by 50% (p<0.05) and left IL-10 production by Treg polarized cells unchanged. MSCs exhibit their typical suppressive phenotype when added early to cell cultures in the presence of CD4 + T cell polarizing stimuli. However, once T cell activation has occurred, MSCs show an opposite stimulating effect on Th17 cells, while leaving Treg IL-10 producing cells unchanged. These results suggest that the therapeutic use of MSCs in vivo might exert opposing effects on disease activity, according to the time of therapeutic application and the level of effector T cell activation.
AB - Mesenchymal stem cells (MSCs) are multipotent progenitors with broad immunosuppressive properties. However, their therapeutic use in autoimmune disease models has shown dissimilar effects when applied at different stages of disease. We therefore investigated the effect of the addition of MSCs on the differentiation of Th1, Treg and Th17 cells in vitro, at different states of CD4 + T cell activation. CD4 + T lymphocytes purified by negative selection from mouse C57BL/6 splenocytes were cultured under Th1, Th17 and Treg inducing conditions with IL-12, TGF-β+IL-6 or TGF-β, respectively. C57BL/6 bone marrow derived MSCs were added to CD4 + T cell cultures at day 0 or after 3 days of T cell polarizing activation. Intracellular cytokines for Th1, Th17 and Treg cells were quantitated at day 6 by flow cytometry. While early addition (day 0) of MSCs suppressed all CD4 + T cell lineages, addition at day 3 only decreased IFN-γ production by Th1 polarized cells by 64% (p<0.05) while markedly increased IL-17 production by Th17 polarized cells by 50% (p<0.05) and left IL-10 production by Treg polarized cells unchanged. MSCs exhibit their typical suppressive phenotype when added early to cell cultures in the presence of CD4 + T cell polarizing stimuli. However, once T cell activation has occurred, MSCs show an opposite stimulating effect on Th17 cells, while leaving Treg IL-10 producing cells unchanged. These results suggest that the therapeutic use of MSCs in vivo might exert opposing effects on disease activity, according to the time of therapeutic application and the level of effector T cell activation.
KW - Mesenchymal stem cells
KW - Th1
KW - Th17 T cells
KW - Treg
UR - http://www.scopus.com/inward/record.url?scp=78751704606&partnerID=8YFLogxK
U2 - 10.1016/j.imlet.2010.09.006
DO - 10.1016/j.imlet.2010.09.006
M3 - Article
C2 - 20888363
AN - SCOPUS:78751704606
SN - 0165-2478
VL - 135
SP - 10
EP - 16
JO - Immunology Letters
JF - Immunology Letters
IS - 1-2
ER -